{"id":"0c2caec0-6756-58f0-8674-b311e4b5f63b","stable_key":"649e861b-265a-5912-bc36-3a73e53ef892:l-serine-hsan-trial-neuropathy","predicate":"improves","statement":"At one year, the L-serine group improved by 1.5 CMTNS units relative to placebo; the 95% confidence interval was -2.8 to -0.1 units.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"34e52190-ff1c-5de9-a92e-bc857458c78c","mechanism_event_label":"A small controlled trial also measured a clinical outcome.","subject":{"id":"c882cd0b-9d83-5b07-bd1c-fe4d45657dcb","slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"},"object":{"id":"62b20308-3738-5eea-a0df-0746c9530877","slug":"human-hsan1-trial-neuropathy-score","display_name":"HSAN1 trial neuropathy score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"34e52190-ff1c-5de9-a92e-bc857458c78c","stable_key":"649e861b-265a-5912-bc36-3a73e53ef892:l-serine-hsan-trial-neuropathy-event","event_type":"observed_relationship","label":"A small controlled trial also measured a clinical outcome.","description":"At one year, the L-serine group improved by 1.5 CMTNS units relative to placebo; the 95% confidence interval was -2.8 to -0.1 units.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c882cd0b-9d83-5b07-bd1c-fe4d45657dcb","slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"62b20308-3738-5eea-a0df-0746c9530877","slug":"human-hsan1-trial-neuropathy-score","display_name":"HSAN1 trial neuropathy score","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same HSAN1 randomized trial as the lipid result; not independent participants.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small rare-disease trial; benefit cannot be transferred to other neuropathies or ALS.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Serine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A small controlled trial also measured a clinical outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30626650/ · DOI 10.1212/WNL.0000000000006811","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6fd2b1ed-577f-5552-b45d-61fc239b281d","evidence_kind":"source_excerpt","locator":"Lines 302-308","start_line":302,"end_line":308,"excerpt":"## l-serine-hsan-trial-neuropathy\nA small controlled trial also measured a clinical outcome.\nAt one year, the L-serine group improved by 1.5 CMTNS units relative to placebo; the 95% confidence interval was -2.8 to -0.1 units.\nModel: Same HSAN1 randomized trial as the lipid result; not independent participants.\nLimitations: Small rare-disease trial; benefit cannot be transferred to other neuropathies or ALS.\nEvidence access: Primary abstract\nRandomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30626650/ · DOI 10.1212/WNL.0000000000006811","model_system":"Same HSAN1 randomized trial as the lipid result; not independent participants.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"70bcf57a-36bb-563f-9073-2d616e5f155a","stable_key":"import-649e861b-265a-5912-bc36-3a73e53ef892","title":"L-Serine: synthesis, one-carbon metabolism, lipids and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"22a750ce2b94f8607268c58322c48c4f0468f403b72a4008307538a6e5ff86d5","revision_id":"c1d6a7e1-9558-5bc6-9e3b-7080c26d3dbc","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}